NAMS (NewAmsterdam Pharma Co NV) Tariff Resilience Score: 6/10 (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NAMS NewAmsterdam Pharma Co NV NAMS
45 GF Score
Price $27.96
GF Value $10.42
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is NewAmsterdam Pharma Co NV Tariff Resilience Score?

NewAmsterdam Pharma Co NV NAMS +1.05% 45 Tariff Resilience Score is 6 as of Aug. 08, 2026. GuruFocus rates NAMS with a GF Score™ of 45/100 and a GF Value™ of $10.42 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,367 Biotechnology companies, NewAmsterdam Pharma Co NV ranks better than 76.01% on this metric.

NewAmsterdam Pharma Co NV has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

NewAmsterdam Pharma Co NV has NAMS operates in the pharmaceutical sector, which often benefits from tariff exemptions. Its supply chain is diversified, and it primarily serves European markets. Historical tariffs have had limited impact, and the company has strong pricing power to mitigate potential costs.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes NewAmsterdam Pharma Co NV might have Average Resilient.

NewAmsterdam Pharma Co NV  (NAS:NAMS) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

NewAmsterdam Pharma Co NV Tariff Resilience Score Related Terms

NAMS vs ARQT, IDYA, ALMS: Tariff Resilience Score Comparison

For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NewAmsterdam Pharma Co NV Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where NewAmsterdam Pharma Co NV's Tariff Resilience Score falls into.


NAMS
45GF Score
NewAmsterdam Pharma Co NV NAMS
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
NewAmsterdam Pharma Co NV (NAMS) has a Tariff Resilience Score of 6 as of Aug. 08, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, NewAmsterdam Pharma Co NV ranks #328 out of 1367 companies in the Biotechnology industry, placing it in the top 24%.
Is NewAmsterdam Pharma Co NV's Tariff Resilience Score too high?
NewAmsterdam Pharma Co NV's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. NewAmsterdam Pharma Co NV's value of 6 is 50% above this industry median. Based on the distribution chart, NewAmsterdam Pharma Co NV ranks #328 out of 1367 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, NewAmsterdam Pharma Co NV has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NewAmsterdam Pharma Co NV's Tariff Resilience Score compare to ARQT and IDYA?
According to the Biotechnology industry distribution chart, NewAmsterdam Pharma Co NV ranks #328 out of 1367 companies for Tariff Resilience Score. This places NewAmsterdam Pharma Co NV in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. NewAmsterdam Pharma Co NV's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,367 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NewAmsterdam Pharma Co NV's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NewAmsterdam Pharma Co NV's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewAmsterdam Pharma Co NV stock overvalued right now?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV (NAMS) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.42, compared to a current price of $27.96 — trading 168.3% above its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. NewAmsterdam Pharma Co NV's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For NewAmsterdam Pharma Co NV (NAMS), the current Tariff Resilience Score is 6 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NewAmsterdam Pharma Co NV (NAMS) Overvalued in 2026?

Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV stock appears to be overvalued. The current stock price of $27.96 is trading 168.3% above its estimated GF Value™ of $10.42. GuruFocus considers NewAmsterdam Pharma Co NV to be Significantly Overvalued.

Key valuation signals for NAMS:

  • Tariff Resilience Score: 6
  • GF Value™: $10.42 vs. price of $27.96 (168.3% above fair value)
  • GF Score™: 45/100 with 3 warning signs
  • Industry Position: 50% above the Biotechnology median (#328 of 1367)

No single metric tells the full story. See the NAMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NewAmsterdam Pharma Co NV Business Description

Other Exchanges KH6:Germany
Address Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
45GF Score

Get the complete analysis for NAMS

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.96
Price
$10.42
GF Value